Opaleye Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Opaleye Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-130,000	Closed	-$7.75M	–	42
2017 Q3	$7.75M	Buy	130,000 +70,000	+117%	+$4.23M	2.74%	13
2017 Q2	$4.73M	Buy	60,000 +10,000	+20%	+$818K	1.98%	18
2017 Q1	$4.15M	Hold	50,000	–	–	2.06%	18
2016 Q4	$3.97M	Sell	50,000 -20,000	-29%	-$1.45M	2.34%	17
2016 Q3	$4.9M	Buy	70,000 +20,000	+40%	+$1.11M	2.56%	12
2016 Q2	$1.94M	Sell	50,000 -10,000	-17%	-$416K	1.3%	31
2016 Q1	$2.43M	Sell	60,000 -25,000	-29%	-$1.59M	1.52%	28
2015 Q4	$7.54M	Buy	85,000 +11,800	+16%	+$932K	3.15%	10
2015 Q3	$5.42M	Buy	73,200 +23,200	+46%	+$1.93M	2.67%	16
2015 Q2	$4.04M	Buy	+50,000	New	+$3.26M	1.61%	25

Other funds holding EGRX

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

HEC

Hudson Executive Capital New York $50.9M AUM 22.11% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management's EGRX Position: Q4 2017 in Review

Opaleye Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2017, closing a stake of 130,000 shares — an estimated $7.75M sold.

Opaleye Management first reported a position in EGRX in Q2 2015 and held it in 10 quarters. The position peaked at $7.75M in Q3 2017. 170 funds tracked by Wall St. Rank hold EGRX as of Q4 2017.

Opaleye Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Opaleye Management sold 130,000 Eagle Pharmaceuticals, Inc. shares in Q4 2017, an estimated $7.75M.
Opaleye Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 10 quarters.
Opaleye Management's Eagle Pharmaceuticals, Inc. position peaked at $7.75M in Q3 2017.
170 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2017.

Based on Opaleye Management's 13F filing for Q4 2017, filed 9 Feb 2018.